Skip to main content

Advertisement

SpringerLink
Log in

Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention.

Method and design

This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment (n = 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure (n = 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present.

Results

The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group (P = 0.01). Additionally, there was no mortality or a need for hemodialysis in either group.

Conclusion

In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McCullough P (2007) Renal complication of contrast media. In: King Spencer B interventional cardiology, 1st edn, chapter 23, McGraw-Hill, China

  2. Brar SS, Shen AYJ, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N et al (2008) Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography. A randomized trial. JAMA 300(9):1038–1046

    Article  CAS  PubMed  Google Scholar 

  3. Roozbeh J, Jahromi AH, Sharifian M, Pakfetrat M, Afsharinia R (2008) Protective effect of pentoxifylline on contrast induced nephropathy, Saudi. J Kidney Dis Transpl 19:985–986

    Google Scholar 

  4. Ferrario F, Barone MT, Landoni G, Genderini A, Heidemperger M, Trezzi M et al (2009) Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy—a randomized controlled study. Nephrol Dial Transpl 24(10):3103–3107

    Article  CAS  Google Scholar 

  5. Gomes VO, Poli CE, Figueredo DE, Caramori P, Lasevitch R, Bodanese LC, Araujol A et al (2005) N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 91:774–778

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Huber W, Hennig M, Rosenbrock H, Wacker A, Saur D (2006) Prophylaxis of contrast material—induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 239:793–804

    Article  PubMed  Google Scholar 

  7. Amini M, Salarifar M, Amirbaigloo A, Masoudkabi F, Esfahani F (2009) N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials 10:45

    Article  PubMed Central  PubMed  Google Scholar 

  8. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL et al (2009) N-acetylcysteine versus ascorbic acid for preventing contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study—a prospective randomized controlled trial. Am Heart J 157(3):576–583

    Article  CAS  PubMed  Google Scholar 

  9. Ng TM, Shurmur SW, Silver M, Nissen LR, O’Leary EL, Rigmaiden RS, Cieciorka M et al (2006) Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). Int J Cardiol 109(3):322–328

    Article  PubMed  Google Scholar 

  10. Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P et al (2004) N-acetylcysteine versus fenoldopammesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 44(4):762–765

    Article  CAS  PubMed  Google Scholar 

  11. Bagshaw SM, Ghali WA (2005) Theophylline for prevention of contrast-induced nephropathy. Arch Intern Med 165:1087–1093

    Article  PubMed  Google Scholar 

  12. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N (2002) The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transpl 17(11):1936–1941

    Article  CAS  Google Scholar 

  13. Walker PD, Brokering KL, Theobald JC (2003) Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Pharmacotherapy 23(12):1617–1626

    Article  CAS  PubMed  Google Scholar 

  14. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS et al (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate. A randomized controlled trial. JAMA 291:2328–2334

    Article  CAS  PubMed  Google Scholar 

  15. Kanbay M, Covic A, Coca SG, Turgut F, Akcay A, Parikh CR (2009) Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. Int Urol Nephrol 41(3):617–627

    Article  CAS  PubMed  Google Scholar 

  16. Kooiman J, Sijpkens YW, de Vries JP, Brulez HF, Hamming JF, van der Molen AJ, Aarts NJ, Cannegieter SC, Putter H, Swarts R, van den Hout WB, Rabelink TJ, Huisman MV (2014) A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography. Nephrol Dial Transpl 29(5):1029–1036

    Article  CAS  Google Scholar 

  17. Spargias K, Alexopoulos E, Kyrzopoulos S, Iacovis P, Greenwood DC, Manginas A et al (2004) Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110:2837–2842

    Article  CAS  PubMed  Google Scholar 

  18. Boscheri A, Weinbrenner C, Botzek B, Reynen K, Kuhlisch E, Strasser RH (2007) Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol 68(5):279–286

    Article  CAS  PubMed  Google Scholar 

  19. Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD et al (1999) Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 83(2):260–263, A5

  20. Staudinger T, Presterl E, Graninger W, Locker GJ, Knapp S et al (1996) Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Intensive Care Med 22(9):888–893

    Article  CAS  PubMed  Google Scholar 

  21. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, McCann WP (1998) Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 32:64–71

    Article  CAS  PubMed  Google Scholar 

  22. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S (2002) A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62:2202–2207

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Interventional Cardiology, Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

    Ata Firouzi, Mohsen Maadani, Reza Kiani, Farshad Shakerian, Hamid Reza Sanati, Ali Zahedmehr & Seyedabbas Nabavi

  2. Cardiac electrophysiology research center, Rajaie cardiovascular medical and research center, Iran university of medical sciences, Tehran, Iran

    Mona Heidarali

Authors
  1. Ata Firouzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohsen Maadani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reza Kiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farshad Shakerian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hamid Reza Sanati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ali Zahedmehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Seyedabbas Nabavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mona Heidarali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Reza Kiani.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Firouzi, A., Maadani, M., Kiani, R. et al. Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention. Int Urol Nephrol 47, 521–525 (2015). https://doi.org/10.1007/s11255-014-0890-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-014-0890-z

Keywords

Search

Navigation